$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Donepezil (Aricept) imported drug name and comparison of differences with domestic versions
2026-02-01 22:25:32
Check Details
Analysis of possible causes of skin changes after taking Fidaxomicin for six days
2026-02-01 22:25:32
Check Details
Standard usage and dosage of ponatinib and dosage adjustment recommendations for different patients
2026-02-01 22:25:32
Check Details
Why Trelagliptin cannot be taken casually and analysis of possible risks caused by abuse
2026-02-01 22:25:32
Check Details
Possible risks and countermeasures after sudden discontinuation of Inalisate (Iheli)
2026-02-01 22:25:32
Check Details
Analysis of the price of abatacept (Enrisu) and price differences in different regions
2026-02-01 22:25:32
Check Details
Description of the main functions, efficacy and therapeutic mechanism of Almonertinib
2026-02-01 22:25:32
Check Details
Which patients can use giritinib/segatan?
2026-02-01 22:25:32
Check Details
Why is Midostaurin so expensive?
2026-02-01 22:25:32
Check Details
How to know the dosage and usage of cabergoline
2026-02-01 22:25:32
Check Details
Momelotinib appears to have good safety profile in MF treatment
2026-02-01 22:25:32
Check Details
The success rate of 28-day blockade treatment with Bituvi/Bikonprenol Tablets
2026-02-01 22:25:32
Check Details
1
2
...
1912
1913
1914
1915
1916
1917
1918
...
10226
10227
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Comprehensive Interpretation of Osimertinib: Efficacy, Side Effects and Medication Standards
2
Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?
3
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
4
Asciminib (SCEMBLIX): STAMP Inhibitor Dosing Guide and Nomenclature Clarification for CML
5
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights
6
Cabergoline Medication Guide: Contraindications, Treatment Costs, and Safety Monitoring Essentials
7
Pemigatinib vs. Anlotinib: Key Differences Between FGFR-Targeted Therapy and Multi-Target Anti-Angiogenic Treatment
8
Enasidenib (IDHIFA): A Comprehensive Guide to Targeted Therapy for IDH2-Mutated Acute Myeloid Leukemia
9
Midostaurin vs. Gilteritinib: Key Differences in FLT3-Targeted AML Therapy
10
Lapatinib: A Targeted Anticancer Agent — Not Merely Symptom Relief
11
Filgotinib: Mechanism of Action and Clinical Applications Explained
12
Lapatinib: Proper Administration Guide and Key Precautions